JP2002506061A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002506061A5 JP2002506061A5 JP2000535629A JP2000535629A JP2002506061A5 JP 2002506061 A5 JP2002506061 A5 JP 2002506061A5 JP 2000535629 A JP2000535629 A JP 2000535629A JP 2000535629 A JP2000535629 A JP 2000535629A JP 2002506061 A5 JP2002506061 A5 JP 2002506061A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylaryl
- alkylheteroaryl
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000217 alkyl group Chemical group 0.000 description 105
- 125000002877 alkyl aryl group Chemical group 0.000 description 48
- 125000001072 heteroaryl group Chemical group 0.000 description 46
- 125000005213 alkyl heteroaryl group Chemical group 0.000 description 45
- 125000003118 aryl group Chemical group 0.000 description 45
- 150000001875 compounds Chemical class 0.000 description 32
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 27
- 201000010099 disease Diseases 0.000 description 24
- 0 C*C*(CC(N(C(*)C(N*)=O)N(*)C=C)O)NC Chemical compound C*C*(CC(N(C(*)C(N*)=O)N(*)C=C)O)NC 0.000 description 22
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 18
- 239000000203 mixture Substances 0.000 description 13
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 8
- 125000004005 formimidoyl group Chemical group [H]\N=C(/[H])* 0.000 description 8
- 230000001404 mediated effect Effects 0.000 description 8
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 208000020084 Bone disease Diseases 0.000 description 4
- 206010009900 Colitis ulcerative Diseases 0.000 description 4
- 208000011231 Crohn disease Diseases 0.000 description 4
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 4
- 208000034578 Multiple myelomas Diseases 0.000 description 4
- 206010033645 Pancreatitis Diseases 0.000 description 4
- 206010035226 Plasma cell myeloma Diseases 0.000 description 4
- 201000004681 Psoriasis Diseases 0.000 description 4
- 229910006074 SO2NH2 Inorganic materials 0.000 description 4
- 206010040070 Septic Shock Diseases 0.000 description 4
- 206010052779 Transplant rejections Diseases 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 201000006704 Ulcerative Colitis Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 229910052799 carbon Inorganic materials 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 206010014599 encephalitis Diseases 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 206010034674 peritonitis Diseases 0.000 description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 description 4
- 230000036303 septic shock Effects 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- ZCHCHJQEWYIJDQ-UHFFFAOYSA-N Cc1ncc[o]1 Chemical compound Cc1ncc[o]1 ZCHCHJQEWYIJDQ-UHFFFAOYSA-N 0.000 description 3
- 125000000753 cycloalkyl group Chemical group 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 208000030507 AIDS Diseases 0.000 description 2
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 2
- 201000004384 Alopecia Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 206010055128 Autoimmune neutropenia Diseases 0.000 description 2
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 2
- 208000023328 Basedow disease Diseases 0.000 description 2
- 201000006474 Brain Ischemia Diseases 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 description 2
- 206010008909 Chronic Hepatitis Diseases 0.000 description 2
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 2
- 208000035473 Communicable disease Diseases 0.000 description 2
- 208000001490 Dengue Diseases 0.000 description 2
- 206010012310 Dengue fever Diseases 0.000 description 2
- 206010014596 Encephalitis Japanese B Diseases 0.000 description 2
- 206010018364 Glomerulonephritis Diseases 0.000 description 2
- 208000015023 Graves' disease Diseases 0.000 description 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 description 2
- 208000005176 Hepatitis C Diseases 0.000 description 2
- 206010019773 Hepatitis G Diseases 0.000 description 2
- 206010019755 Hepatitis chronic active Diseases 0.000 description 2
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 102100037850 Interferon gamma Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000000589 Interleukin-1 Human genes 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 102100039898 Interleukin-18 Human genes 0.000 description 2
- 201000005807 Japanese encephalitis Diseases 0.000 description 2
- 241000710842 Japanese encephalitis virus Species 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 2
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 2
- 206010039710 Scleroderma Diseases 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 206010043781 Thyroiditis chronic Diseases 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 208000003152 Yellow Fever Diseases 0.000 description 2
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 201000005000 autoimmune gastritis Diseases 0.000 description 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000025729 dengue disease Diseases 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 208000027866 inflammatory disease Diseases 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 208000021039 metastatic melanoma Diseases 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 206010028417 myasthenia gravis Diseases 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 230000001338 necrotic effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 230000000926 neurological effect Effects 0.000 description 2
- 206010036067 polydipsia Diseases 0.000 description 2
- 230000002062 proliferating effect Effects 0.000 description 2
- 208000002320 spinal muscular atrophy Diseases 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- 206010043554 thrombocytopenia Diseases 0.000 description 2
- OHDUVVJZRCKZGF-UHFFFAOYSA-N C/C(/c(cc1Cl)ccc1NC(C)=O)=[O]\C Chemical compound C/C(/c(cc1Cl)ccc1NC(C)=O)=[O]\C OHDUVVJZRCKZGF-UHFFFAOYSA-N 0.000 description 1
- ZXDOYBCWIYHFED-UHFFFAOYSA-N CC(C(c(c(OC)ccc1)c1OC)=O)=O Chemical compound CC(C(c(c(OC)ccc1)c1OC)=O)=O ZXDOYBCWIYHFED-UHFFFAOYSA-N 0.000 description 1
- BVQVLAIMHVDZEL-UHFFFAOYSA-N CC(C(c1ccccc1)=O)=O Chemical compound CC(C(c1ccccc1)=O)=O BVQVLAIMHVDZEL-UHFFFAOYSA-N 0.000 description 1
- PXIPZIPSDBXFQR-UHFFFAOYSA-N CC(C1)C(C)OC1=O Chemical compound CC(C1)C(C)OC1=O PXIPZIPSDBXFQR-UHFFFAOYSA-N 0.000 description 1
- DGMFYKIFASMWGY-ZZMKPFPKSA-N CC([C@@H](CC[C@H](C)C1)[C@H]1O)I Chemical compound CC([C@@H](CC[C@H](C)C1)[C@H]1O)I DGMFYKIFASMWGY-ZZMKPFPKSA-N 0.000 description 1
- VGVXDPRCTIRHOO-UHFFFAOYSA-N CC(c(cc1)cc(Cl)c1N)=O Chemical compound CC(c(cc1)cc(Cl)c1N)=O VGVXDPRCTIRHOO-UHFFFAOYSA-N 0.000 description 1
- GMTSPBYBJKGPJF-UHFFFAOYSA-N CC(c(cc1)cc(Cl)c1O)=O Chemical compound CC(c(cc1)cc(Cl)c1O)=O GMTSPBYBJKGPJF-UHFFFAOYSA-N 0.000 description 1
- BMHMKWXYXFBWMI-UHFFFAOYSA-N CC(c(cc1)cc2c1OCO2)=O Chemical compound CC(c(cc1)cc2c1OCO2)=O BMHMKWXYXFBWMI-UHFFFAOYSA-N 0.000 description 1
- JLPKZJDZXIKSCP-UHFFFAOYSA-N CC(c(cc1Cl)cc(Cl)c1N)=O Chemical compound CC(c(cc1Cl)cc(Cl)c1N)=O JLPKZJDZXIKSCP-UHFFFAOYSA-N 0.000 description 1
- FXSIZYWHUQEXPC-UHFFFAOYSA-N CC(c(cc1Cl)cc(Cl)c1O)=O Chemical compound CC(c(cc1Cl)cc(Cl)c1O)=O FXSIZYWHUQEXPC-UHFFFAOYSA-N 0.000 description 1
- LOVTYJVFDHMSKW-UHFFFAOYSA-N CC(c(cc1Cl)cc(Cl)c1OC)=O Chemical compound CC(c(cc1Cl)cc(Cl)c1OC)=O LOVTYJVFDHMSKW-UHFFFAOYSA-N 0.000 description 1
- PPNGALBGZJBTRY-UHFFFAOYSA-N CC(c1cc(C(c2ccccc2)=O)ccc1)=O Chemical compound CC(c1cc(C(c2ccccc2)=O)ccc1)=O PPNGALBGZJBTRY-UHFFFAOYSA-N 0.000 description 1
- XSAYZAUNJMRRIR-UHFFFAOYSA-N CC(c1cc2ccccc2cc1)=O Chemical compound CC(c1cc2ccccc2cc1)=O XSAYZAUNJMRRIR-UHFFFAOYSA-N 0.000 description 1
- PLHBJRPIYKTQOU-UHFFFAOYSA-N CC(c1ccc2[nH]cnc2c1)=O Chemical compound CC(c1ccc2[nH]cnc2c1)=O PLHBJRPIYKTQOU-UHFFFAOYSA-N 0.000 description 1
- FZNZYQKOSUHWLG-UHFFFAOYSA-O CC(c1cccc(C2)c1-c1c2cccc1)=[OH+] Chemical compound CC(c1cccc(C2)c1-c1c2cccc1)=[OH+] FZNZYQKOSUHWLG-UHFFFAOYSA-O 0.000 description 1
- IISCTCINLRAMDK-UHFFFAOYSA-N CC(c1cccc-2c1Cc1c-2cccc1)=O Chemical compound CC(c1cccc-2c1Cc1c-2cccc1)=O IISCTCINLRAMDK-UHFFFAOYSA-N 0.000 description 1
- SERGXQDYIIZXGF-UHFFFAOYSA-N CC(c1cccc2c1-c1ccccc1C2=O)=O Chemical compound CC(c1cccc2c1-c1ccccc1C2=O)=O SERGXQDYIIZXGF-UHFFFAOYSA-N 0.000 description 1
- XWKLDJFMOIYQIP-UHFFFAOYSA-N CC(c1cccc2c1ccc(CC(c1nc3ccccc3cc1)=O)c2)=O Chemical compound CC(c1cccc2c1ccc(CC(c1nc3ccccc3cc1)=O)c2)=O XWKLDJFMOIYQIP-UHFFFAOYSA-N 0.000 description 1
- BEWYHVAWEKZDPP-UHFFFAOYSA-N CC1(C)C2(C)CCC1CC2 Chemical compound CC1(C)C2(C)CCC1CC2 BEWYHVAWEKZDPP-UHFFFAOYSA-N 0.000 description 1
- OSCGIZXZULALRT-UHFFFAOYSA-N CC1C=CN=CC1 Chemical compound CC1C=CN=CC1 OSCGIZXZULALRT-UHFFFAOYSA-N 0.000 description 1
- MBHINSULENHCMF-UHFFFAOYSA-N CCC(N(C)C)=O Chemical compound CCC(N(C)C)=O MBHINSULENHCMF-UHFFFAOYSA-N 0.000 description 1
- UOWJRXRXBDZRQQ-UHFFFAOYSA-N CCC(N(CC1)CCN1C(C)=O)=O Chemical compound CCC(N(CC1)CCN1C(C)=O)=O UOWJRXRXBDZRQQ-UHFFFAOYSA-N 0.000 description 1
- YEQAMPOYHLICPF-UHFFFAOYSA-N CCC(N1CCNCC1)=O Chemical compound CCC(N1CCNCC1)=O YEQAMPOYHLICPF-UHFFFAOYSA-N 0.000 description 1
- DLEWDCPFCNLJEY-UHFFFAOYSA-N CCC(N1CCOCC1)=O Chemical compound CCC(N1CCOCC1)=O DLEWDCPFCNLJEY-UHFFFAOYSA-N 0.000 description 1
- VIJUZNJJLALGNJ-UHFFFAOYSA-N CCCC(N(C)C)=O Chemical compound CCCC(N(C)C)=O VIJUZNJJLALGNJ-UHFFFAOYSA-N 0.000 description 1
- FFSAXUULYPJSKH-UHFFFAOYSA-N CCCC(c1ccccc1)=O Chemical compound CCCC(c1ccccc1)=O FFSAXUULYPJSKH-UHFFFAOYSA-N 0.000 description 1
- WDKVKTWYQRIBRM-UHFFFAOYSA-N CCCN(CC1)CCC1C#N Chemical compound CCCN(CC1)CCC1C#N WDKVKTWYQRIBRM-UHFFFAOYSA-N 0.000 description 1
- DSNYFFJTZPIKFZ-UHFFFAOYSA-N CCCOc1ccccc1 Chemical compound CCCOc1ccccc1 DSNYFFJTZPIKFZ-UHFFFAOYSA-N 0.000 description 1
- HXDOZKJGKXYMEW-UHFFFAOYSA-N CCc(cc1)ccc1O Chemical compound CCc(cc1)ccc1O HXDOZKJGKXYMEW-UHFFFAOYSA-N 0.000 description 1
- UZQDJMCQCORWDC-UHFFFAOYSA-N CCc1c[nH]c(-c2cccc(CC)c2)n1 Chemical compound CCc1c[nH]c(-c2cccc(CC)c2)n1 UZQDJMCQCORWDC-UHFFFAOYSA-N 0.000 description 1
- NRGGMCIBEHEAIL-UHFFFAOYSA-N CCc1ccccn1 Chemical compound CCc1ccccn1 NRGGMCIBEHEAIL-UHFFFAOYSA-N 0.000 description 1
- VJXRKZJMGVSXPX-UHFFFAOYSA-N CCc1ccncc1 Chemical compound CCc1ccncc1 VJXRKZJMGVSXPX-UHFFFAOYSA-N 0.000 description 1
- MFEIKQPHQINPRI-UHFFFAOYSA-N CCc1cnccc1 Chemical compound CCc1cnccc1 MFEIKQPHQINPRI-UHFFFAOYSA-N 0.000 description 1
- HTSABYAWKQAHBT-RQJHMYQMSA-N C[C@H](CCC1)C[C@H]1O Chemical compound C[C@H](CCC1)C[C@H]1O HTSABYAWKQAHBT-RQJHMYQMSA-N 0.000 description 1
- FYIORKUEZVVKEL-UHNVWZDZSA-N C[C@H](COC1)[C@H]1O Chemical compound C[C@H](COC1)[C@H]1O FYIORKUEZVVKEL-UHNVWZDZSA-N 0.000 description 1
- ITQTTZVARXURQS-UHFFFAOYSA-N Cc1cnccc1 Chemical compound Cc1cnccc1 ITQTTZVARXURQS-UHFFFAOYSA-N 0.000 description 1
- KFQRNFCDUHEOCO-UHFFFAOYSA-N Cc1nc(cccc2C)c2[o]1 Chemical compound Cc1nc(cccc2C)c2[o]1 KFQRNFCDUHEOCO-UHFFFAOYSA-N 0.000 description 1
- BSKHPKMHTQYZBB-UHFFFAOYSA-N Cc1ncccc1 Chemical compound Cc1ncccc1 BSKHPKMHTQYZBB-UHFFFAOYSA-N 0.000 description 1
- VLLNJDMHDJRNFK-UHFFFAOYSA-N OC1(CC(C2)C3)CC3CC2C1 Chemical compound OC1(CC(C2)C3)CC3CC2C1 VLLNJDMHDJRNFK-UHFFFAOYSA-N 0.000 description 1
- UWZPVNHPLZEAAA-UHFFFAOYSA-N OC1C(CC23)CC4C2C3C1C4 Chemical compound OC1C(CC23)CC4C2C3C1C4 UWZPVNHPLZEAAA-UHFFFAOYSA-N 0.000 description 1
- XCIXKGXIYUWCLL-UHFFFAOYSA-N OC1CCCC1 Chemical compound OC1CCCC1 XCIXKGXIYUWCLL-UHFFFAOYSA-N 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N OC1CCCCC1 Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- KMGCKSAIIHOKCX-UHFFFAOYSA-N OC1Cc2ccccc2C1 Chemical compound OC1Cc2ccccc2C1 KMGCKSAIIHOKCX-UHFFFAOYSA-N 0.000 description 1
- ISQVBYGGNVVVHB-UHFFFAOYSA-N OCC1CCCC1 Chemical compound OCC1CCCC1 ISQVBYGGNVVVHB-UHFFFAOYSA-N 0.000 description 1
- VSSAZBXXNIABDN-UHFFFAOYSA-N OCC1CCCCC1 Chemical compound OCC1CCCCC1 VSSAZBXXNIABDN-UHFFFAOYSA-N 0.000 description 1
- BDLILEKJUQHKJK-UHFFFAOYSA-N OCCCc1cc(C2NCCN(CCO)C2)ccc1 Chemical compound OCCCc1cc(C2NCCN(CCO)C2)ccc1 BDLILEKJUQHKJK-UHFFFAOYSA-N 0.000 description 1
- KZTWONRVIPPDKH-UHFFFAOYSA-N OCCN1CCCCC1 Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 1
- KKFDCBRMNNSAAW-UHFFFAOYSA-N OCCN1CCOCC1 Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 1
- HROUXFIBPSXDJB-UHFFFAOYSA-N OCC[n]1nnnc1 Chemical compound OCC[n]1nnnc1 HROUXFIBPSXDJB-UHFFFAOYSA-N 0.000 description 1
- WVDDGKGOMKODPV-UHFFFAOYSA-N OCc1ccccc1 Chemical compound OCc1ccccc1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 1
- XDPCNPCKDGQBAN-BYPYZUCNSA-N O[C@@H]1COCC1 Chemical compound O[C@@H]1COCC1 XDPCNPCKDGQBAN-BYPYZUCNSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Oc1ccccc1 Chemical compound Oc1ccccc1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7732798P | 1998-03-09 | 1998-03-09 | |
| US60/077,327 | 1998-03-09 | ||
| PCT/US1999/005124 WO1999046248A1 (en) | 1998-03-09 | 1999-03-09 | 1,2-diazepane derivatives as interleukin-1beta converting enzyme inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002506061A JP2002506061A (ja) | 2002-02-26 |
| JP2002506061A5 true JP2002506061A5 (enExample) | 2006-04-27 |
| JP4499917B2 JP4499917B2 (ja) | 2010-07-14 |
Family
ID=22137418
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000535629A Expired - Fee Related JP4499917B2 (ja) | 1998-03-09 | 1999-03-09 | インターロイキン−１β変換酵素のインヒビターとしての１，２−ジアゼパン誘導体 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US6426413B1 (enExample) |
| EP (1) | EP1062210B1 (enExample) |
| JP (1) | JP4499917B2 (enExample) |
| AT (1) | ATE296812T1 (enExample) |
| AU (1) | AU2901899A (enExample) |
| DE (1) | DE69925581T2 (enExample) |
| ES (1) | ES2244178T3 (enExample) |
| WO (1) | WO1999046248A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040185039A1 (en) * | 2002-08-30 | 2004-09-23 | Heinz Kohler | Therapeutic applications of noncovalent dimerizing antibodies |
| US20050033033A1 (en) * | 1998-05-04 | 2005-02-10 | Heinz Kohler | Trans-membrane-antibody induced inhibition of apoptosis |
| US7569674B2 (en) * | 1998-05-04 | 2009-08-04 | Innexus Biotechnology International Limited | Autophilic antibodies |
| US20090208418A1 (en) * | 2005-04-29 | 2009-08-20 | Innexus Biotechnology Internaltional Ltd. | Superantibody synthesis and use in detection, prevention and treatment of disease |
| WO2001021599A1 (en) * | 1999-09-17 | 2001-03-29 | Lg Chemical Ltd. | Caspase inhibitor |
| US7253169B2 (en) | 1999-11-12 | 2007-08-07 | Gliamed, Inc. | Aza compounds, pharmaceutical compositions and methods of use |
| US6417189B1 (en) * | 1999-11-12 | 2002-07-09 | Gpi Nil Holdings, Inc. | AZA compounds, pharmaceutical compositions and methods of use |
| US7655616B2 (en) * | 2001-05-25 | 2010-02-02 | Ares Trading S.A. | Use of IL-18 inhibitors for treating head injuries |
| TR201809678T4 (tr) | 2001-06-26 | 2018-07-23 | Amgen Fremont Inc | Opgl ye karşi antikorlar. |
| UA78516C2 (en) * | 2001-08-10 | 2007-04-10 | Applied Research Systems | Use of inhibitors of il-18 for treatment and/or prevention of hypersensitivity disorders, and in particular of delayed-type hypersensitivity |
| IL166241A0 (en) * | 2002-07-29 | 2006-01-15 | Rigel Pharmaceuticals Inc | Method of treating or preventing autoimmune diseases with 2,4-pyrimidinedinediamine compounds |
| MXPA05002514A (es) | 2002-09-06 | 2005-05-27 | Amgen Inc | Anticuerpo monoclonal anti-il-1r1 humano terapeutico. |
| AU2003275304A1 (en) * | 2002-10-01 | 2004-04-23 | Musc Oundation For Research Development | Use of caspase inhibitors as therapeutic agent against radiation-induced injury |
| GB0329572D0 (en) * | 2003-12-20 | 2004-01-28 | Astrazeneca Ab | Amide derivatives |
| PL217743B1 (pl) * | 2004-05-15 | 2014-08-29 | Vertex Pharma | Zastosowanie inhibitorów ICE/kaspazy-1 do leczenia napadów i konwulsji w epilepsji oraz zawierające je kompozycja farmaceutyczna i zestaw |
| KR20080038369A (ko) * | 2005-07-28 | 2008-05-06 | 버텍스 파마슈티칼스 인코포레이티드 | 카스파제 억제제 프로드럭 |
| AR056806A1 (es) | 2005-11-14 | 2007-10-24 | Amgen Inc | Moleculas quimericas de anticuerpo rankl- pth/ pthrp |
| ES2296484B1 (es) * | 2005-11-23 | 2009-04-01 | Fundacion De La Comunidad Valenciana Centro De Investigacion Principe Felipe (90%) | Composicion farmaceutica para inhibir la apoptosis. |
| EP3836954B1 (en) | 2018-08-13 | 2025-05-07 | Iltoo Pharma | Combination of interleukin-2 with an interleukin 1 inhibitor, conjugates and therapeutic uses thereof |
| WO2023225277A1 (en) * | 2022-05-19 | 2023-11-23 | Ohio State Innovation Foundation | Peptidyl flavor modifiers |
Family Cites Families (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5874424A (en) | 1995-12-20 | 1999-02-23 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β converting enzyme |
| US6204261B1 (en) | 1995-12-20 | 2001-03-20 | Vertex Pharmaceuticals Incorporated | Inhibitors of interleukin-1β Converting enzyme inhibitors |
| US4465679A (en) | 1983-01-31 | 1984-08-14 | Usv Pharmaceutical Corporation | 1,2-Diaza-3-one compounds, their use in treating hypertension and pharmaceutical compositions thereof |
| IL72523A (en) | 1983-08-12 | 1988-06-30 | Takeda Chemical Industries Ltd | 3-amino-4-oxo-2,3,4,5-tetrahydro-1,5-benzoxazepine derivatives,their production and pharmaceutical compositions containing them |
| US5055451A (en) | 1986-12-22 | 1991-10-08 | Syntex Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
| US5158936A (en) | 1986-12-22 | 1992-10-27 | Syntex (U.S.A.) Inc. | Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors |
| US5008245A (en) | 1988-10-27 | 1991-04-16 | University Of Kentucky Research Foundation | Novel peptidyl carbamate inhibitors of the enzyme elastase |
| ZA905737B (en) | 1989-07-26 | 1991-05-29 | Merrell Dow Pharma | Novel peptidase inhibitors |
| NZ235155A (en) | 1989-09-11 | 1993-04-28 | Merrell Dow Pharma | Peptidase substrates in which the carboxy terminal group has been replaced by a tricarbonyl radical |
| WO1991015577A1 (en) | 1990-04-04 | 1991-10-17 | Black, Roy, A. | INTERLEUKIN 1'beta' PROTEASE |
| US5416013A (en) | 1990-04-04 | 1995-05-16 | Sterling Winthrop Inc. | Interleukin 1β protease and interleukin 1β protease inhibitors |
| DE69226820T2 (de) | 1991-06-21 | 1999-05-12 | Merck & Co., Inc., Rahway, N.J. | Peptidylderivate als Inhibitoren von Interleukin-1B-konvertierenden Enzymen |
| JP3190431B2 (ja) | 1991-07-01 | 2001-07-23 | 三菱化学株式会社 | ケトン誘導体 |
| US5278061A (en) | 1991-08-16 | 1994-01-11 | Merck & Co., Inc. | Affinity chromatography matrix useful in purifying interleukin-1β converting enzyme |
| US6348570B1 (en) | 1991-08-16 | 2002-02-19 | Merck & Co., Inc. | Chromophore containing compounds and their use in determining interleukin-1β convertase activity |
| EP0533226A3 (en) | 1991-08-16 | 1993-08-18 | Merck & Co. Inc. | Novel chromophore containing compounds |
| DE69229252T2 (de) | 1991-08-16 | 1999-12-16 | Merck & Co., Inc. | DNS, welche das Interleukin-1B-Vorläufer-Converting-Enzym kodiert |
| RU2206611C2 (ru) | 1991-08-30 | 2003-06-20 | Вертекс Фармасьютикалз Инкорпорейтед | ФРАГМЕНТ ДНК, ПЛАЗМИДНЫЙ ВЕКТОР, СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА И ПОЛИПЕПТИД, ОБЛАДАЮЩИЙ IL-1β ПРОТЕАЗНОЙ АКТИВНОСТЬЮ |
| GB9123326D0 (en) | 1991-11-04 | 1991-12-18 | Sandoz Ltd | Improvements in or relating to organic compounds |
| EP0547699A1 (en) | 1991-12-19 | 1993-06-23 | Merck & Co. Inc. | Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme |
| AU3479593A (en) | 1992-01-31 | 1993-09-01 | Merck & Co., Inc. | Peptidyl derivatives as inhibitors of interleukin-1beta converting enzyme |
| CA2129976C (en) | 1992-02-21 | 2002-09-17 | Kevin T. Chapman | Peptidyl derivatives as inhibitors of interleukin-1.beta. converting enzyme |
| JPH08500242A (ja) | 1992-06-24 | 1996-01-16 | メルク エンド カンパニー インコーポレーテッド | インターロイキン１β前駆体の転換酵素をコードするＤＮＡ |
| CA2139854A1 (en) | 1992-07-31 | 1994-02-17 | Ralph P. Robinson | Peptidyl 4-amino-2, 2-difluoro-3-oxo-1, 6-hexanedioic acid derivatives as antiinflammatory agents |
| CA2109646C (en) | 1992-11-24 | 2000-03-07 | Gaston O. Daumy | Para-nitroanilide peptides |
| EP0618223A3 (en) | 1993-03-08 | 1996-06-12 | Sandoz Ltd | Peptides, the release of Interleukin 1-Bêta, useful as anti-inflammatory agents. |
| CA2122227A1 (en) | 1993-04-29 | 1994-10-30 | Roland E. Dolle | Peptide analogs as irreversible interleukin-1.beta. protease inhibitors |
| US5462939A (en) | 1993-05-07 | 1995-10-31 | Sterling Winthrop Inc. | Peptidic ketones as interleukin-1β-converting enzyme inhibitors |
| US5411985A (en) | 1993-05-17 | 1995-05-02 | Merck & Co., Inc. | Gamma-pyrone-3-acetic acid as an inhibitor or interleukin-1 β inventory enzyme |
| JPH0789951A (ja) | 1993-06-03 | 1995-04-04 | Sterling Winthrop Inc | インターロイキン−１β転換酵素阻害剤 |
| ATE170868T1 (de) | 1993-06-04 | 1998-09-15 | Vertex Pharma | Peptid-phosphinyloxymethyl-ketonen als inhibitoren von interleukin-1 beta- konvertierenden enzymen |
| US5446128A (en) * | 1993-06-18 | 1995-08-29 | The Board Of Trustees Of The University Of Illinois | Alpha-helix mimetics and methods relating thereto |
| WO1995000160A1 (en) | 1993-06-24 | 1995-01-05 | The General Hospital Corporation | Programmed cell death genes and proteins |
| WO1995005192A1 (en) | 1993-08-13 | 1995-02-23 | Merck & Co., Inc. | SUBSTITUTED KETONE DERIVATIVES AS INHIBITORS OF INTERLEUKIN-1β CONVERTING ENZYME |
| US5486623A (en) | 1993-12-08 | 1996-01-23 | Prototek, Inc. | Cysteine protease inhibitors containing heterocyclic leaving groups |
| US5714484A (en) | 1993-12-08 | 1998-02-03 | Prototek, Inc. | α-(1,3-dicarbonylenol ether) methyl ketones as cysteine protease inhibitors |
| CN1118458C (zh) | 1994-03-31 | 2003-08-20 | 弗特克斯药品有限公司 | 作为白细胞介素抑制剂的嘧啶基衍生物 |
| CA2189036A1 (en) | 1994-04-29 | 1995-11-09 | Roland E. Dolle | Halomethyl amides as il-1.beta. protease inhibitors |
| US5492824A (en) | 1994-05-12 | 1996-02-20 | Basf Ag | Ice and ice-like compositions and methods of making same |
| US5552400A (en) * | 1994-06-08 | 1996-09-03 | Sterling Winthrop Inc. | Fused-bicyclic lactams as interleukin-1β converting enzyme inhibitors |
| US5856116A (en) | 1994-06-17 | 1999-01-05 | Vertex Pharmaceuticals, Incorporated | Crystal structure and mutants of interleukin-1 beta converting enzyme |
| US5716929A (en) | 1994-06-17 | 1998-02-10 | Vertex Pharmaceuticals, Inc. | Inhibitors of interleukin-1β converting enzyme |
| US5565430A (en) | 1994-08-02 | 1996-10-15 | Sterling Winthrop Inc. | Azaaspartic acid analogs as interleukin-1β converting enzyme inhibitors |
| US5498616A (en) | 1994-11-04 | 1996-03-12 | Cephalon, Inc. | Cysteine protease and serine protease inhibitors |
| TW394764B (en) | 1995-02-14 | 2000-06-21 | Mitsubishi Chemcal Corp | Oxygen-containing heterocyclic derivatives |
| CA2215211A1 (en) | 1995-03-31 | 1996-10-03 | Takeda Chemical Industries, Ltd. | Cysteine protease inhibitor |
| US5635504A (en) * | 1995-06-07 | 1997-06-03 | Bristol-Myers Squibb Co. | Diazepine containing dual action inhibitors |
| JPH11511463A (ja) | 1995-08-31 | 1999-10-05 | スミスクライン・ビーチャム・コーポレイション | インターロイキン変換酵素およびアポプトーシス |
| WO1997007805A1 (en) | 1995-08-31 | 1997-03-06 | Smithkline Beecham Corporation | Interleukin converting enzyme and apoptosis |
| WO1997024339A1 (en) | 1995-12-27 | 1997-07-10 | Ono Pharmaceutical Co., Ltd. | Tetrazole derivatives and drugs containing the same as the active ingredient |
| WO1998004539A1 (en) | 1996-07-29 | 1998-02-05 | Mitsubishi Chemical Corporation | Oxygenic heterocyclic derivatives |
| JP2000501428A (ja) | 1996-09-12 | 2000-02-08 | アイドゥン ファーマシューティカルズ，インコーポレイテッド | 酵素のｉｃｅ／ｃｅｄ−３プロテアーゼファミリーを阻害する新規な三環式化合物 |
| ATE310528T1 (de) | 1996-09-12 | 2005-12-15 | Idun Pharmaceuticals Inc | Hemmung der apoptose unter verwendung von inhibitoren der interleukin-1 beta converting enzym (ice)/ced-3 familie |
| JP3492703B2 (ja) | 1996-09-12 | 2004-02-03 | アイドゥン ファーマシューティカルズ，インコーポレイテッド | システインプロテアーゼのＩＣＥ／ｃｅｄ―３ファミリーの阻害剤としてのＣ―末端変性（Ｎ―置換）―２―インドリルジペプチド |
| HUP9700816A3 (en) | 1997-04-28 | 1999-06-28 | Gyogyszerkutato Intezet | 3(r)-3-amino-4-carboxy-butiraldehyde derivatives inhibiting release of interleukin-1-beta |
-
1999
- 1999-03-09 JP JP2000535629A patent/JP4499917B2/ja not_active Expired - Fee Related
- 1999-03-09 AU AU29018/99A patent/AU2901899A/en not_active Abandoned
- 1999-03-09 ES ES99909935T patent/ES2244178T3/es not_active Expired - Lifetime
- 1999-03-09 EP EP99909935A patent/EP1062210B1/en not_active Expired - Lifetime
- 1999-03-09 WO PCT/US1999/005124 patent/WO1999046248A1/en not_active Ceased
- 1999-03-09 DE DE69925581T patent/DE69925581T2/de not_active Expired - Lifetime
- 1999-03-09 AT AT99909935T patent/ATE296812T1/de not_active IP Right Cessation
-
2000
- 2000-09-05 US US09/654,855 patent/US6426413B1/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002506878A5 (enExample) | ||
| JP3971704B2 (ja) | 一酸化窒素合成酵素阻害物質であるリン酸塩 | |
| DE69122084T2 (de) | 2-arylthiazolderivat sowie dieses enthaltendes arzneimittel | |
| US7923557B2 (en) | Process for preparing trisubstituted pyrimidine compounds | |
| RU2000126298A (ru) | Ингибиторы каспаз | |
| JP2003531103A5 (enExample) | ||
| RU2263113C2 (ru) | Производные 8,8а-дигидроиндено [1,2-d]тиазола, содержащие в положении 2 заместитель с сульфонамидной или сульфоновой структурой, способ их получения и их применение в качестве лекарственного средства | |
| JP2001522780A (ja) | オメプラゾールの新規な結晶形 | |
| DE68926729T2 (de) | Benzopyranderivate mit einer blutdrucksenkenden Wirkung | |
| JP2004504388A5 (enExample) | ||
| WO1993004035A1 (de) | Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel | |
| DE69015322T2 (de) | Substituierte Zyklobutendion-Verbindungen. | |
| JP2006507220A5 (enExample) | ||
| CA2526991A1 (en) | Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor | |
| DE69718498T2 (de) | Substituierte benzoylthiazolderivate und sie enthaltende medikamente | |
| CA1244431A (en) | Phenylpiperazine derivatives and process for producing the same | |
| AU766295B2 (en) | Utilization of polycyclic 2-amino-thiazole systems in the production of medicaments for prophylaxis or treatment of obesity | |
| JP2007525503A5 (enExample) | ||
| TWI822457B (zh) | Ｄｐ拮抗劑 | |
| AU763111B2 (en) | Polycyclic 2-amino-thiazole systems, method for the production thereof and medicament containing said compounds | |
| RU2004103079A (ru) | Новые иммуномодулирующие соединения | |
| JP2005528367A5 (enExample) | ||
| CA2441331A1 (en) | Bicyclic guanidine derivatives and therapeutic uses thereof | |
| EP0315112B1 (en) | Novel amide compounds | |
| DE68902576D1 (de) | Verwendung von thiadiazol-oxid-derivaten zur herstellung einer pharmazeutischen zusammensetzung fuer die behandlung von stoerungen der gastrointestinalen mobilitaet. |